Vaxcyte (PCVX) recently reported full enrollment in its OPUS-1 and OPUS-2 Phase 3 trials for VAX-31, a key step toward a potential Biologics License Application that investors often monitor closely.
See our latest analysis for Vaxcyte.
The recent completion of enrollment in the OPUS-1 and OPUS-2 trials comes alongside strong momentum, with a 90 day share price return of 25.66% and a 1 year total shareholder return of 84.75%, while the latest share price stands at US$58.38.
If this kind of clinical progress has your attention, it can be useful to see what else is moving in related areas by scanning 36 healthcare AI stocks.
With shares up 25.66% over 90 days and trading at US$58.38 against an implied intrinsic discount of roughly 36%, the key question now is simple: is Vaxcyte still mispriced or has the market already priced in future growth?
Most Popular Narrative: 46.4% Undervalued
With Vaxcyte last closing at $58.38 against a narrative fair value of $109.00, the valuation gap hinges heavily on what happens with VAX-31 and broader vaccine demand.
Expanded adult pneumococcal vaccination recommendations in the US and increasing adoption of adult PCV programs internationally are enlarging the addressable market for higher valency vaccines such as VAX-31. This directly relates to potential future revenue scale.
Want to understand why this pre revenue company still screens as deeply undervalued? The core narrative leans on aggressive revenue ramp assumptions, margin uplift from maturing biotech peers, and a premium future earnings multiple rarely seen outside high growth sectors.
Result: Fair Value of $109 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on OPUS and infant VAX-31 data meeting expectations and on Vaxcyte managing rising R&D and manufacturing costs without eroding its cash runway.
Find out about the key risks to this Vaxcyte narrative.
Next Steps
Think this story sounds either too optimistic or too cautious? Take a closer look at the full picture for yourself, including the 1 key reward and 2 important warning signs
Ready for more investment ideas?
If Vaxcyte has sharpened your focus, do not stop here. Broaden your watchlist with targeted ideas that could fit different goals and risk levels.
- Spot potential turnaround stories early by scanning 33 elite penny stocks with strong financials that meet clear financial quality filters instead of guessing on the riskiest names.
- Zero in on quality at a discount by reviewing the 59 high quality undervalued stocks that combine strong fundamentals with attractive pricing signals.
- Build a steadier income focused watchlist by checking out the 13 dividend fortresses that pair higher yields with a focus on resilience.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com